GliaPharm is a Swiss biotechnology company that develops treatments for neurological and psychiatric disorders.
GliaPharm’s innovative therapeutic approach is to target glial cells to promote brain metabolism and neuroprotection. Even though they are the predominant type of cell in the brain, the importance of glial cells has been ignored by the pharmaceutical industry who to date have focused almost exclusively on neuronal cells. GliaPharmʼs pioneering approach hence represents a highly innovative and unexplored solution for the treatment of neurological disorders.
GliaPharm has developed a proprietary technology platform, GliaX™, to identify molecules that target glial cells. The pipeline of molecules identified through the GliaX™ platform consists of over fifty molecules, four of which are at different stages of validation. Primary target indications include Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), two orphan neurodegenerative diseases that share similar metabolic deficits and are lacking effective therapeutic solutions.
GliaPharm is a spinoff of a leading laboratory in the field of brain metabolism and glial cell biology led by Prof. Magistretti’s laboratory at EPFL (Lausanne, Switzerland). The company is located at the Campus Biotech in Geneva.